For millions of people with knee osteoarthritis, the path from conservative care to joint replacement can stretch across more than a decade, leaving a vast middle ground where existing options have fallen short. Under President and CEO Christopher Gleason, Moximed is building a new category around that gap, combining a joint-preserving implant, long-term clinical evidence, and a leadership team with deep experience turning novel medtech therapies into standards of care.
Christopher Gleason has spent much of his career in a particular corner of medtech: the space between an established standard of care and an entirely new way of treating patients.
He helped build businesses at NeoTract and Relievant Medsystems, companies that introduced new treatment approaches in urology and chronic pain before being acquired by Teleflex and Boston Scientific, respectively. When he encountered Moximed, he recognized a familiar opportunity.
“Commercializing completely new and different approaches to address gaps in treatment, where no solution is ideal for patients and physicians, all the way through to standard of care has been the focus of my career,” Gleason said.
Moximed offered that challenge at scale.
Approximately 15 million people in the U.S. are under care for symptomatic knee osteoarthritis, according to the company. The disease affects patients across a remarkably broad age range. Moximed has treated people from their 20s through their 80s. Yet the treatment pathway remains divided between interventions that can eventually lose effectiveness and surgery that many patients either do not yet need or do not want.
Moximed estimates that approximately 30% of the symptomatic population is treated with conservative approaches such as bracing, hyaluronic acid injections, physical therapy, and weight loss. Another 8% has reached the point at which end-stage surgical treatment may be appropriate. Between them sit an estimated 9 million patients, or 62% of the population, in what Moximed describes as the treatment gap.
Patients can spend an average of 13 years in that gap. Of the 9 million, Moximed estimates that approximately 4 million already fall within the current indication for its MISHA Knee System: patients with activity-restricting pain who have failed non-surgical care and are unwilling to undergo or are not indicated for total knee arthroplasty.
For Gleason, that is not simply an underserved population. It is the foundation for an entirely new treatment category.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry. The Lens is what the sharpest minds in medtech are reading to stay ahead. Packed with expert perspectives, market analysis, and high-impact insight, it’s an essential edge for the ones building, leading, and betting on this industry.
Join the LSI Mailing List
Upcoming Events
17011 Beach Blvd, Suite 500
Huntington Beach, CA 92647
© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy | Your Privacy Choices | Delete my Data